Compares two chemotherapy combinations as first treatment for a blood cancer
Compares R-CMOP and R-CHOP in adults with newly diagnosed lymphoma.
Plain-language title generated from the registry record
Registry title: Safety and Efficacy of R-CMOP Versus R-CHOP in the Initial Treatment of DLBCL
Key facts
- Where
- Beijing, Fuzhou, Ganzhou, Guangzhou, Guilin, Lanzhou, Nanchang, Shenzhen, and Zhuhai, ChinaSee the 10 sites
- Phase
- Phase 1/2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT06760039, who can take part
Where in China
- Beijing Tongren HospitalBeijing, ChinaNot yet recruiting
- Fujian Provincial Cancer HospitalFuzhou, ChinaNot yet recruiting
- Ganzhou Cancer HospitalGanzhou, ChinaNot yet recruiting
- The Affiliated Hospital of Guangdong Medical UniversityGuangzhou, ChinaNot yet recruiting
- The Fifth Affiliated Hospital of Guangzhou Medical UniversityGuangzhou, ChinaTaking people
- Guangxi Zhuang Autonomous Region Cancer HospitalGuilin, ChinaNot yet recruiting
- Gansu Provincial Cancer HospitalLanzhou, ChinaNot yet recruiting
- Jiangxi Provincial Cancer HospitalNanchang, ChinaNot yet recruiting
- Shenzhen People's HospitalShenzhen, ChinaNot yet recruiting
- The Fifth Affiliated Hospital of Sun Yat-sen UniversityZhuhai, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Sun Yat-sen University
- Trial code
- NCT06760039
- Record updated
- 3 April 2025
- Original description
This is a prospective, randomized, controlled, multicenter, phase II clinical trial to evaluate the efficacy and safety of R-CMOP versus R-CHOP in the initial treatment of low-risk and medium-risk diffuse large B-cell lymphoma (DLBCL).Read full original descriptionShow less
Safety and Efficacy of R-CMOP Versus R-CHOP in the Initial Treatment of Low-risk and Medium-risk Diffuse Large B-cell Lymphoma (DLBCL): a Randomized, Controlled, Open-label, Multicenter, Phase Ib/II Clinical Study
This is a prospective, randomized, controlled, multicenter, phase II clinical trial to evaluate the efficacy and safety of R-CMOP versus R-CHOP in the initial treatment of low-risk and medium-risk diffuse large B-cell lymphoma (DLBCL).
Inclusion: Aged ≥18,≤80 years, both male and female; Pathologically confirmed DLBCL; No prior treatment for DLBCL; There must be at least one measurable or evaluable lesion that meets the evaluation criteria for Lugano 2014 lymphoma; Eastern Cooperative Oncology Group (ECOG) performance status score of 0-; Expected survival ≥3 months; International Prognostic Index (IPI) ≤ 2; Sufficient bone marrow, liver, and kidney function.
Exclusion: The patients had previously received antitumor therapy; Patients with the infection of human immunodeficiency virus (HIV) and/or acquired immunodeficiency syndrome; Pregnant and lactating women and subjects of childbearing age who do not want to use contraception; Other types of LBCL:Primary Cutaneous Diffuse Large B-cell Lymphoma (Leg Type), Primary Mediastinal (Thymic) Large B-cell Lymphoma, Lymphomatoid Granulomatosis, ALK-positive Diffuse Large B-cell Lymphoma, Plasmablastic Lymphoma, Intravascular Large B-cell Lymphoma, T-cell/Histiocyte-rich Large B-cell Lymphoma, and others; Transformed DLBCL; Patients with central nervous system involvement, or those who require high-dose methotrexate for prevention; Mentally ill persons or persons unable to obtain informed consent; The investigators think that the patient is not suitable for the study.